These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12817195)

  • 41. Drug cost. States concerned about Fuzeon.
    AIDS Policy Law; 2003 Apr; 18(7):5. PubMed ID: 12728848
    [No Abstract]   [Full Text] [Related]  

  • 42. Use of darunavir and enfuvirtide in a pregnant woman.
    Sued O; Lattner J; Gun A; Patterson P; Abusamra L; Cesar C; Fink V; Krolewiecki A; Cahn P
    Int J STD AIDS; 2008 Dec; 19(12):866-7. PubMed ID: 19050223
    [TBL] [Abstract][Full Text] [Related]  

  • 43. T-20 phase III studies underway.
    Giles C
    Surviv News (Atlanta Ga); 2001 Oct; ():1, 12. PubMed ID: 11708190
    [No Abstract]   [Full Text] [Related]  

  • 44. Therapies. Raising the limits.
    Cohen J
    Science; 2002 Jun; 296(5577):2322. PubMed ID: 12089423
    [No Abstract]   [Full Text] [Related]  

  • 45. New class of medications approved for advance HIV.
    FDA Consum; 2003; 37(3):5. PubMed ID: 12793380
    [No Abstract]   [Full Text] [Related]  

  • 46. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
    Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697
    [No Abstract]   [Full Text] [Related]  

  • 47. ConFuzeon reigns.
    Huff B
    GMHC Treat Issues; 2003 Apr; 17(4):10. PubMed ID: 12751446
    [No Abstract]   [Full Text] [Related]  

  • 48. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1.
    Pérez-Alvarez L; Carmona R; Ocampo A; Asorey A; Miralles C; Pérez de Castro S; Pinilla M; Contreras G; Taboada JA; Nájera R
    J Med Virol; 2006 Feb; 78(2):141-7. PubMed ID: 16372284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV fusion inhibitors.
    Pozniak A
    J HIV Ther; 2001 Nov; 6(4):91-4. PubMed ID: 11740409
    [No Abstract]   [Full Text] [Related]  

  • 50. The optimal use of enfuvirtide.
    Gallant JE
    Hopkins HIV Rep; 2003 May; 15(3):1-3. PubMed ID: 12809103
    [No Abstract]   [Full Text] [Related]  

  • 51. Enfuvirtide, an HIV-1 fusion inhibitor.
    Jenny-Avital ER
    N Engl J Med; 2003 Oct; 349(18):1770-1; author reply 1770-1. PubMed ID: 14593994
    [No Abstract]   [Full Text] [Related]  

  • 52. T-20 small program, CD4 < 50, will enroll November 27 at 3:00 P.M.
    James JS
    AIDS Treat News; 2001 Oct; (373):3. PubMed ID: 11768880
    [No Abstract]   [Full Text] [Related]  

  • 53. [Fusion proteins in HIV-AIDS treatment].
    Hennemann A
    Med Monatsschr Pharm; 2003 Sep; 26(9):300-2. PubMed ID: 14526613
    [No Abstract]   [Full Text] [Related]  

  • 54. Enfuvirtide, the first fusion inhibitor to treat HIV infection.
    Poveda E; Briz V; Soriano V
    AIDS Rev; 2005; 7(3):139-47. PubMed ID: 16302461
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Initial retroviral drug with new mechanism of action. Peptide T-20 enriches therapeutic arsenal].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():55-7. PubMed ID: 15011591
    [No Abstract]   [Full Text] [Related]  

  • 56. T-20 being called "miraculous".
    AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412581
    [No Abstract]   [Full Text] [Related]  

  • 57. Immunologic benefits of enfuvirtide in patients enrolled in a drug assistance program.
    Saberi P; Caswell NH; Gruta CI; Tokumoto JN; Dong BJ
    Ann Pharmacother; 2008 May; 42(5):621-6. PubMed ID: 18413688
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.
    Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI
    Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [New therapeutic options in protracted HIV-infected patients with virological failure].
    Moreno Cuerda VJ; Rubio García R; Morales Conejo M
    Med Clin (Barc); 2008 Jan; 130(2):66-70. PubMed ID: 18221677
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New-Fill on "hold" and open-label for T-20.
    Berger DS
    Posit Aware; 2002; 13(1):64-5. PubMed ID: 12216532
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.